Literature DB >> 28340233

Increase in Drug Overdose Deaths Involving Fentanyl-Rhode Island, January 2012-March 2014.

Melissa C Mercado1,2,3, Steven A Sumner2,3, M Bridget Spelke4, Michele K Bohm1, David E Sugerman5, Christina Stanley6.   

Abstract

Objective: This study identified sociodemographic, substance use, and multiple opioid prescriber and dispenser risk factors among drug overdose decedents in Rhode Island, in response to an increase in overdose deaths (ODs) involving fentanyl.
Methods: This cross-sectional investigation comprised all ODs reviewed by Rhode Island's Office of the State Medical Examiners (OSME) during January 2012 to March 2014. Data for 536 decedents were abstracted from OSME's charts, death certificates, toxicology reports, and Prescription Monitoring Program (PMP) databases. Decedents whose cause of death involved illicit fentanyl (N = 69) were compared with decedents whose causes of death did not involve fentanyl (other drug decedents; N = 467).
Results: Illicit-fentanyl decedents were younger than other drug decedents (P = 0.005). While more other-drug decedents than illicit fentanyl decedents had postmortem toxicological evidence of consuming heroin (31.9% vs 19.8%, P < 0.001) and various pharmaceutical substances (P = 0.002-0.027), third party reports indicated more recent heroin use among illicit fentanyl decedents (62.3% vs 45.6%, P = 0.002). Approximately 35% of decedents filled an opioid prescription within 90 days of death; of these, one-third had a mean daily dosage greater than 100 morphine milligram equivalents (MME/day). Most decedents' opioid prescriptions were filled at one to two dispensers (83.9%) and written by one to two prescribers (75.8%). Notably, 29.2% of illicit fentanyl and 10.5% of other drug decedents filled prescriptions for buprenorphine, which is used to treat opioid use disorders. Conclusions: Illicit-fentanyl deaths frequently involved other illicit drugs (e.g., cocaine, heroin). The proportion of all decedents acquiring greater than 100 MME/day prescription dosages written and/or filled by few prescribers and dispensers is concerning. To protect patients, prescribers and dispensers should review PMP records and substance abuse history prior to providing opioids.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28340233      PMCID: PMC5587352          DOI: 10.1093/pm/pnx015

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  22 in total

Review 1.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

2.  Supply-side response to declining heroin purity: fentanyl overdose episode in New Jersey.

Authors:  Katherine Hempstead; Emel O Yildirim
Journal:  Health Econ       Date:  2013-06-06       Impact factor: 3.046

3.  CDC grand rounds: prescription drug overdoses - a U.S. epidemic.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-01-13       Impact factor: 17.586

4.  Increasing deaths from opioid analgesics in the United States.

Authors:  Leonard J Paulozzi; Daniel S Budnitz; Yongli Xi
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-09       Impact factor: 2.890

5.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

6.  The history and development of the fentanyl series.

Authors:  T H Stanley
Journal:  J Pain Symptom Manage       Date:  1992-04       Impact factor: 3.612

7.  Detection of fentanyl and its analogs by enzyme-linked immunosorbent assay.

Authors:  W Ruangyuttikarn; M Y Law; D E Rollins; D E Moody
Journal:  J Anal Toxicol       Date:  1990 May-Jun       Impact factor: 3.367

8.  Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines - United States, 2012.

Authors:  Leonard J Paulozzi; Karin A Mack; Jason M Hockenberry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-04       Impact factor: 17.586

9.  Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013.

Authors:  Christopher M Jones; Joseph Logan; R Matthew Gladden; Michele K Bohm
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-07-10       Impact factor: 17.586

10.  Notes from the field: increase in fentanyl-related overdose deaths - Rhode Island, November 2013-March 2014.

Authors:  Melissa C Mercado-Crespo; Steven A Sumner; M Bridget Spelke; David E Sugerman; Christina Stanley
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-06-20       Impact factor: 17.586

View more
  13 in total

1.  The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015.

Authors:  Alexander Y Walley; Dana Bernson; Marc R Larochelle; Traci C Green; Leonard Young; Thomas Land
Journal:  Public Health Rep       Date:  2019-10-02       Impact factor: 2.792

2.  New Data on Opioid Use and Prescribing in the United States.

Authors:  Anne Schuchat; Debra Houry; Gery P Guy
Journal:  JAMA       Date:  2017-08-01       Impact factor: 56.272

3.  Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island.

Authors:  Shayla Nolen; Xiao Zang; Avik Chatterjee; Czarina N Behrends; Traci C Green; Aranshi Kumar; Benjamin P Linas; Jake R Morgan; Sean M Murphy; Alexander Y Walley; Shapei Yan; Bruce R Schackman; Brandon D L Marshall
Journal:  Addiction       Date:  2021-12-05       Impact factor: 7.256

Review 4.  Tramadol Prescription over a 4-Year Period in the USA.

Authors:  Luisa M Bigal; Kristen Bibeau; Stephanie Dunbar
Journal:  Curr Pain Headache Rep       Date:  2019-08-06

5.  High Prevalence of Self-Reported Exposure to Adulterated Drugs Among People Who Experienced an Opioid Overdose in Canada: A Cohort Study.

Authors:  Amy Prangnell; Christopher Fairgrieve; Ekaterina Nosova; Kora DeBeck; M-J Milloy; Kanna Hayashi
Journal:  Subst Use Misuse       Date:  2019-01-20       Impact factor: 2.164

6.  Physician Prescribing of Opioids to Patients at Increased Risk of Overdose From Benzodiazepine Use in the United States.

Authors:  Joseph A Ladapo; Marc R Larochelle; Alexander Chen; Melissa M Villalon; Stefanie Vassar; David Y C Huang; John N Mafi
Journal:  JAMA Psychiatry       Date:  2018-06-01       Impact factor: 21.596

7.  Preventing Overdose Using Information and Data from the Environment (PROVIDENT): protocol for a randomized, population-based, community intervention trial.

Authors:  Brandon D L Marshall; Nicole Alexander-Scott; Jesse L Yedinak; Benjamin D Hallowell; William C Goedel; Bennett Allen; Robert C Schell; Yu Li; Maxwell S Krieger; Claire Pratty; Jennifer Ahern; Daniel B Neill; Magdalena Cerdá
Journal:  Addiction       Date:  2021-11-29       Impact factor: 6.526

8.  Mitragynine Attenuates Morphine Withdrawal Effects in Rats-A Comparison With Methadone and Buprenorphine.

Authors:  Rahimah Hassan; Cheah Pike See; Sasidharan Sreenivasan; Sharif M Mansor; Christian P Müller; Zurina Hassan
Journal:  Front Psychiatry       Date:  2020-05-07       Impact factor: 4.157

9.  Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women.

Authors:  Janitza L Montalvo-Ortiz; Zhongshan Cheng; Henry R Kranzler; Huiping Zhang; Joel Gelernter
Journal:  Sci Rep       Date:  2019-03-15       Impact factor: 4.379

10.  Machine learning takes a village: Assessing neighbourhood-level vulnerability for an overdose and infectious disease outbreak.

Authors:  Jesse L Yedinak; Yu Li; Maxwell S Krieger; Katharine Howe; Colleen Daley Ndoye; Hyunjoon Lee; Anna M Civitarese; Theodore Marak; Elana Nelson; Elizabeth A Samuels; Philip A Chan; Thomas Bertrand; Brandon D L Marshall
Journal:  Int J Drug Policy       Date:  2021-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.